Home » Stocks » TROV

TrovaGene, Inc. (TROV)

May 8, 2020 - Stock symbol was changed to CRDF
Stock Price: $1.19 USD 0.00 (0.00%)
Updated May 7, 2020 4:00 PM EDT
Market Cap 15.89M
Revenue (ttm) 250,632
Net Income (ttm) n/a
Shares Out 11.92M
EPS (ttm) -2.31
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 7, 2020
Last Price $1.19
Previous Close $1.19
Change ($) 0.00
Change (%) 0.00%
Day's Open -
Day's Range 1.16 - 1.19
Day's Volume 0
52-Week Range 0.70 - 3.46

News

Hide News
Zacks Investment Research - 1 year ago

Trovagene (TROV) successfully completes a phase Ib study, evaluating onvansertib in combination with standard-of-care in AML patients. The regimen is well tolerated and safe.

Benzinga - 1 year ago

TrovaGene Inc (NASDAQ: TROV) shares, which had been on a downtrend since early April, reversed course in mid-August.

Seeking Alpha - 1 year ago

TrovaGene announced that it had achieved a positive finding using its drug onvansertib in combination with AbbVie's Venclexta in relapsed or refractory AML patients.

Other stocks mentioned: ABBV
Benzinga - 1 year ago

It's déjà vu for biotech investors, who witnessed a wild rally in Bio-Path Holdings Inc (NASDAQ: BPTH) this week.

About TROV

Trovagene, a clinical-stage, oncology therapeutic company, develops drugs to treat various types of cancer, including leukemia, lymphomas, and solid tumors. Its lead drug candidate is onvansertib, a Polo-like Kinase 1 selective adenosine triphosphate competitive inhibitor that is in Phase Ib/II clinical trial in acute myeloid leukemia (AML); has completed a Phase I clinical trial in advanced solid tumors; and Phase Ib/II clinical trial for metastatic Colorectal Cancer in combination with FOLFIRI and Avastin. The onvansertib is also in Phase II ... [Read more...]

Industry
Biotechnology
Founded
1999
CEO
Thomas H. Adams
Employees
12
Stock Exchange
NASDAQ
Ticker Symbol
TROV
Full Company Profile